<DOC>
	<DOCNO>NCT01120912</DOCNO>
	<brief_summary>The study non-randomized , open label , single dose , single blind , placebo control , single center , single arm study Type I diabetes patient . The study include single dose administration evaluation single dose acute toxicity , pharmacokinetics activity .</brief_summary>
	<brief_title>Safety Efficacy Single Administration Oshadi Oral Insulin Type I Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Stable type I diabetes mellitus . Male/female 18 year old . Glucose level treat s.c basal/bolus insulin injection ( insulin pump ) least 48 hour prior study initiation . Patients must understand willing give write informed consent prior study procedure evaluation willing adhere study schedule requirement . Patients must sterile infertile use approve method contraception time first dose study medication take three month follow study completion discontinuation . Any history significant cardiac , renal , neurologic , metabolic , pulmonary , gastrointestinal , hematologic abnormality , chronic hepatic disease disease judgment investigator would interfere study confound result . Patients positive HIV serology positive HBsAg screening . History evidence active liver disease . Cpeptide &gt; 3 mg/ml ( fast ) . Hba1c &lt; 10 . eGFR &gt; 60 . Female patient breastfeed positive pregnancy test screening time study . Inability give write informed consent . History alcohol drug abuse within 6 month screen . Patients positive urine drug screen substance abuse ( benzodiazepine , THC , opiates , amphetamine , cocaine ) screening . Mental disorder . Patients poor venous access . Significant swallow disorder . Digestive disorder . Small bowel surgery . Mall absorption disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>oral insulin</keyword>
</DOC>